Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2

The aim of this study was to estimate the immunogenic effect of mRNA vaccine against SARS-CoV-2. This study included 510 participants who received mRNA vaccine. The measurement of anti-COVID-19 antibodies was performed using the Abbott SARS-CoV-2 IgG quantitative assay (Abbott). Overall, mean titer...

Descripción completa

Detalles Bibliográficos
Autores principales: Konstantinidis, Theocharis G., Zisaki, Stavroula, Mitroulis, Ioannis, Konstantinidou, Eleni, Kontekaki, Eftychia G., Romanidou, Gioulia, Karvelas, Alexandros, Nanousi, Ioanna, Lazidis, Leonidas, Cassimos, Dimitrios, Tsigalou, Christina, Martinis, Georges, Panopoulou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268570/
https://www.ncbi.nlm.nih.gov/pubmed/34199029
http://dx.doi.org/10.3390/jcm10132842
Descripción
Sumario:The aim of this study was to estimate the immunogenic effect of mRNA vaccine against SARS-CoV-2. This study included 510 participants who received mRNA vaccine. The measurement of anti-COVID-19 antibodies was performed using the Abbott SARS-CoV-2 IgG quantitative assay (Abbott). Overall, mean titer of anti-Spike antibodies was 19,319.2 ± 1787.5 AU/mL. Vaccination induced a robust immunogenic response in those previously infected with SARS-CoV-2 compared with non-infected subjects. Additionally, individuals that were asymptomatic after vaccination produced lower levels of antibodies compared to feverish individuals. In conclusion, remarkably high levels of anti-Spike COVID-19 antibodies were observed after vaccination.

Ejemplares similares